Ignite Creation Date:
2024-05-06 @ 12:00 AM
Last Modification Date:
2024-10-26 @ 10:43 AM
Study NCT ID:
NCT01467882
Status:
COMPLETED
Last Update Posted:
2017-07-28
First Post:
2011-11-07
Brief Title:
Efficacy Safety and Pharmacokinetics PK of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
Sponsor:
Debiopharm International SA
Organization:
Debiopharm International SA
Study Overview
Official Title:
An Open-label Non-comparative Multicenter Study on the Efficacy Safety and Pharmacokinetics of Triptorelin Pamoate Embonate 225 mg 6-month Formulation in Patients Suffering From Central Gonadotropin-dependent Precocious Puberty
Status:
COMPLETED
Status Verified Date:
2017-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will investigate the efficacy safety and pharmacokinetics of triptorelin 225 mg 6-month formulation in 44 patients suffering from central precocious puberty The total study duration per patient will be 12 months 48 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None